Since the patient was taking rimegepant for migraines, strong CYP3A4 inhibitors (itraconazole, posaconazole, and voriconazole) were avoided and isavuconazole, a moderate CYP3A4 inhibitor, was selected. Here, CYP3A4 is linked to migraine disorder.